Company Announcements

Further changes in the Board of Directors

Source: RNS
RNS Number : 3039P
ReNeuron Group plc
18 October 2021

ReNeuron Group plc

("ReNeuron" or the "Company")


ReNeuron announces further changes in the Board of Directors


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on changes to the Company's Board of Directors.


Following the recent appointment of Iain Ross as the new Non-Executive Chairman of the Board and Barbara Staehelin's appointment as a Senior Independent Non-Executive Director, the Company is pleased to confirm that, as announced on 6 August, Catherine Isted has now joined the Company as Chief Financial Officer and has been appointed to the ReNeuron Board as an Executive Director. 


In view of these changes Professor Sir Chris Evans OBE, who has long been involved in the Company and on the Board for nearly nine years, hence would shortly be deemed non-independent, has decided now is the right time to stand down from the Board with immediate effect. Chris has agreed to continue to remain as an adviser to the Board.


Iain Ross, Chairman, commented: "Chris has been a major supporter of the Company for nearly 20 years and his contribution has been invaluable. I want to thank him on behalf of the Board & Management for his service and support and for agreeing to be on hand to continue to provide his wise council. These changes highlight our commitment to a balanced and diverse board as we continue to advance our technologies and enhance shareholder value."


Professor Sir Chris Evans said: "I remain absolutely committed to the Company and I am very excited about its prospects under Iain's leadership of the Board and feel now is the right time to let the new team make the necessary changes as it continues to build for the future. I stand ready to help the Board & Management team in any way I can." 



As of the 18 October, the members of the ReNeuron Board of Directors are:


Iain Ross, Non-Executive Chairman


Olav Hellebo, Chief Executive Officer


Catherine Isted, Chief Financial Officer


Barbara Staehelin, Senior Independent Non-Executive Director


Dr Tim Corn MSc FFPM FRCPsych, Non-Executive Director


Mark Evans, Non-Executive Director


Dr Mike Owen Ph.D, Independent Non-Executive Director









Olav Hellebø, Chief Executive Officer

Catherine Isted, Chief Financial Officer

Via Walbrook PR



Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600




Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654




About ReNeuron


ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.


ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.